AstraZeneca PLC

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.

If you purchased AstraZeneca PLC securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


On March 23, 2021, National Institute of Allergy and Infectious Diseases (NIAID) released a statement on AstraZenaca’s COVID-19 vaccine information which stated, “[l]ate Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.” The statement continued, “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”

On this news, AstraZenaca’s American Depositary Share (ADS) price fell in pre-market trading, damaging investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.



自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。